Antibody-drug conjugates in cancer and beyond: progress, promise, and perspectives.

Abstract

Antibody-drug conjugates (ADCs) are transforming cancer therapy by combining antibody specificity with potent cytotoxic agents, enabling targeted tumor cell killing while minimizing systemic toxicity. This special collection of Antibody Therapeutics presents a wide overview of recent advances in ADC research and development. Topics include targeting strategies, antibody formats, innovative payloads and bispecific apoptosis triggers, formulation strategies, toxicity profiling, and conjugation technologies. Together, these contributions reflect the rapid evolution of the ADC field and point toward safer, more effective therapies for cancer and beyond.